CBUS
CibusCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The best-supported positives are continued rice-program progress, defined 2026 partner milestones, a targeted 2027/2028 rice launch path, and cost actions intended to extend cash runway [#PR-2026-03-17].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional financing may still be needed if commercialization or partnering slips beyond management's current runway window.
Momentum
100
Value
41
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.30 · Bull $2.20 · Bear $0.60
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $20.50
Why
Momentum100 · Δ7d -
Value41 · Δ7d +0.0
Sentiment20 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
20
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 99.5 / Value 41.1 / Sentiment 20.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$134.34M
Beta
1.80
Shares Out
76.33M
P/E (TTM) · Derived
-0.6
P/S (TTM)
28.90
P/FCF (TTM) · Derived
-1.79
Rev YoY
+62.6%
EPS YoY
-75.7%
Gross Margin
-29.3%
Op Margin
-2450.7%
Net Debt
$258.04M
Current Ratio
2.37
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology